A compound of formula (I) for use in the prevention or treatment of a bacterial infection wherein R.sup.P1 is either methyl, ethyl, isopropyl, cyclohexyl or phenyl; R.sup.P2 is selected from methyl, ethyl, isopropyl, cyclohexyl and phenyl; R.sup.P3 is either ethyl, isopropyl, cyclohexyl, phenyl or pyridyl; A is either S or Se; R.sup.A is selected from wherein each of Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4 and Y.sup.9 is independently selected from CH or N, wherein at least three of Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4 and Y.sup.9 are CH; V is selected from O, CHOR.sup.O1, NCO.sub.2R.sup.C2 or NR.sup.N2; one of V, Y.sup.6, Y.sup.7 and Y.sup.8 is selected from CH and N, and the others are CH; X is selected from NH, S or O; R.sup.C1 is selected from OR.sup.O2 or NHR.sup.N1; R.sup.O1 is selected from H and C.sub.1-3 unbranched alkyl; R.sup.O2 is C.sub.1-3 unbranched alkyl; R.sup.N1 is selected from H and C.sub.1-3 unbranched alkyl; R.sup.N2 is C.sub.1-3 unbranched alkyl; R.sup.C2 is either C.sub.1-3 unbranched alkyl or C.sub.3-4 branched alkyl; R.sup.C3 is selected from C.sub.1-3 unbranched alkyl and C.sub.2H.sub.4CO.sub.2H; R.sup.C4 is either H or Me; R.sup.C5 is either H or Me; R.sup.C6 represents one or two optional methyl substituents; and n is an integer from 2 to 8.

##STR00001##

Disclosed herein are substituted pyrazinyl acrylic acids of Formula (II): ##STR00001##
and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.

Provided are a bicyclic fused ring such as for example, benzo[d]imidazole, benzo[d][1,2,3]triazole, or 8-oxo-8,9-dihydro-7H-purine derivatives or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the bicyclic fused ring derivative or pharmaceutically acceptable salt thereof has an inhibitory activity against the lysyl oxidase family and can be usefully applied for preventing or treating various diseases associated with the lysyl oxidase family, such as idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), or liver cirrhosis.

The present invention provides compounds, compositions thereof, and methods of using the same.

A phosphine oxide-based compound represented by Formula 1, and an organic light-emitting device including the phosphine oxide-based compound. ##STR00001## wherein Ar.sub.1 through Ar.sub.3, and a, b, and c are defined as in the specification.

Inhibitors of RSV replication of formula RI ##STR00001##
including stereochemically isomeric forms, and salts or solvates thereof, wherein R.sup.22, W, Q, V, Z p, s, and Het have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other RSV inhibitors, in RSV therapy.